aDepartment of Urology, Weill Cornell Medicine, New York, NY, USA bDepartment of Urology, New York Medical College, Valhalla, NY, USA cDivision of Urology, University of Toronto, Toronto, Ontario, Canada dDepartment of Urology, University of Montreal, Montreal, Quebec, Canada
Objective: Minimally invasive treatments for benign prostatic hyperplasia (BPH) have seen an increase in usage in recent years. We aimed to determine what types of events may influence patient search habits related to surgical BPH treatments.
Methods: Google Trends was used to determine the frequency of searches for different minimally invasive and prostatic ablative treatments for BPH in the United States. The procedures including transurethral resection of the prostate (TURP), Aquablation therapy (Aquablation), Greenlight laser therapy (Greenlight), transurethral needle ablation, transurethral microwave thermotherapy, Urolift (prostatic urethral lift [PUL]), Rezum, iTind, holmium laser enucleation of the prostate, simple prostatectomy, and prostatic artery embolization were compared.
Results: From January 1, 2004 to February 28, 2023, the number of internet search queries have increased for TURP, PUL, Rezum, prostatic artery embolization, and holmium laser enucleation of the prostate. There has been a slight decrease in searches for Greenlight, transurethral needle ablation, transurethral microwave thermotherapy, iTind, simple prostatectomy, and Aquablation.
Conclusion: Despite increased searches of alternatives, TURP remains the most searched BPH procedure. Additionally, search habits may be influenced by several factors including government approval, corporate acquisition, and marketing campaigns. It is important for physicians to understand the types of events that may cause patients to inquire about certain treatments for better quality health information and clinical visits.
. [J]. Asian Journal of Urology, 2024, 11(4): 586-590.
Joshua Winograd, Mariel Pressler, Koby Amanhwah, Christina Sze, Ananth Punyala, Dean Elterman, Kevin C. Zorn, Naeem Bhojani, Bilal Chughtai. Search trends in the treatment for benign prostatic hyperplasia: A twenty-year analysis. Asian Journal of Urology, 2024, 11(4): 586-590.
Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology 2012; 79:1111-7.
[2]
Lucas MI, Diaz P, Escobedo FJ, Limbrick BJ, Scotland KB. Online engagement with surgical treatments for benign prostatic hyperplasia: are minimally invasive surgical therapies outpacing the gold standard? J Endourol 2022; 36:554-61.
[3]
Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)dincidence, management, and prevention. Eur Urol 2006; 50:969-80.
doi: 10.1016/j.eururo.2005.12.042
pmid: 16469429
[4]
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part IIdsurgical evaluation and treatment. J Urol 2021; 206:818-26.
[5]
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part Idinitial work-up and medical management. J Urol 2021; 206:806-17.
[6]
Franco JVA, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, et al. Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network metaanalysis. BJU Int 2022; 130:142-56.
[7]
Sciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G, et al. Minimally invasive treatment in benign prostatic hyperplasia (BPH). Technol Cancer Res Treat 2023; 22:15330338231155000. https://doi.org/10.1177/15330338231155000.
[8]
Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of Aquablation® vs. transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2018; 199:1252-61.
doi: S0022-5347(18)30108-3
pmid: 29360529
[9]
Woo MJ, Ha YS, Lee JN, Kim BS, Kim HT, Kim TH, et al. Comparison of surgical outcomes between holmium laser enucleation and transurethral resection of the prostate in patients with detrusor underactivity. Int Neurourol J 2017; 21:46-52.
doi: 10.5213/inj.1732640.320
pmid: 28361512
[10]
Bouhadana D, Nguyen DD, Raizenne B, Vangala SK, Sadri I, Chughtai B, et al. Assessing the accuracy, quality, and readability of information related to the surgical management of benign prostatic hyperplasia. J Endourol 2022; 36:528-34.
[11]
Billing and coding: Rezum® system for benign prostatic (A56083) Centers for Medicare and Medicaid services. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleIdZ56083. [Accessed 28 November 2023].
[12]
NeoTract, Inc. Receives U.S. FDA de novo approval for the Urolift® prostate implant. https://www.neotract.com/posts/news/neotract-inc-receives-u-s-fda-de-novo-approval-for-theurolift-prostate-implant/. [Accessed 28 November 2023].
[13]
Teleflex incorporated completes Acquisition of Neotract. https://www.urolift.com/press-releases/posts/press-releases/teleflex-incorporated-completes-acquisition-of-neotract. [Accessed 28 November 2023].
[14]
PROCEPT BioRobotics Corporation announces closing of upsized initial public offering and full exercise of the underwriters’ option to purchase additional shares. PROCEPT BioRobotics Corp; 2021. https://ir.procept-biorobotics.com/news-releases/newsrelease-details/procept-biorobotics-corporation-announces-closing-upsized/. [Accessed 28 November 2023].
[15]
Olympus acquires Israeli medical device Company Medi-Tate to drive global urology business growth. https://www.olympuseuropa.com/company/en/news/press-releases/2021-05-28t06-00-00/olympus-acquires-israeli-medical-device-company-meditate-to-drive-global-urology-business-growth.html. [Accessed 28 November 2023].
[16]
FDA grants de novo request for PROCEPT BioRobotics Aquabeam ® system. https://www.businesswire.com/news/home/20171221005923/en/FDA-Grants-De-Novo-Request-for-PROCEPT-BioRobotics-AQUABEAM%C2%AE-System. [Accessed 28 November 2023].
[17]
Teleflexdthe UroLift® system receives bronze award for Best New Branded Television Campaign and Honorable Mention in the best branded website category from DTC perspectives. https://investors.teleflex.com/news/news-details/2021/The-UroLift-System-Receives-Bronze-Award-for-Best-New-Branded-Television-Campaign-and-Honorable-Mention-in-the-Best-Branded-Website-Category-from-DTC-Perspectives/default.aspx. [Accessed 28 November 2023].
[18]
The iTind device receives FDA de novo classification order for benign prostatic hyperplasia (BPH) non-surgical treatment device. https://www.prnewswire.com/news-releases/the-itinddevice-receives-fda-de-novo-classification-order-for-benign-prostatic-hyperplasia-bph-non-surgical-treatment-device-301035836.html. [Accessed 28 November 2023].
[19]
U.S. Food and Drug Administration. Office of Device Evaluation. GreenLight XPS laser system 510(k). https://www.accessdata.fda.gov/cdrh_docs/pdf6/k062719.pdf. [Accessed 28 November 2023].
[20]
Zhang J, Yan J, Guan Y, Sun X, Tian X, Ji K. The history of prostatic arterial embolization. In: Wang M, editor. Prostatic arterial embolization: key techniques. Singapore: Springer; 2021. p. 13-20.
[21]
Large T. The history of prostate enucleation. https://urologichistory.museum/collections/the-scope-of-urology-newsletter/issue-6-summer-2021/the-history-of-prostate-enucleation. [Accessed 28 March 2023].
[22]
Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180:241-5.
doi: 10.1016/j.juro.2008.03.039
pmid: 18499180
[23]
Lee MS, Assmus M, Agarwal D, Large T, Krambeck A. Contemporary practice patterns of transurethral therapies for benign prostate hypertrophy: results of a worldwide survey. World J Urol 2021; 39:4207-13.
doi: 10.1007/s00345-021-03760-z
pmid: 34143283
[24]
Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res 2018; 10:29-43.
[25]
Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) survey. Int J Clin Pract 2008; 62:18-26.
doi: 10.1111/j.1742-1241.2007.01635.x
pmid: 18028388
[26]
Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006; 60:1157-65.
[27]
Sandhu JS, Bixler BR, DahmP, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol 2024; 211:11-9.
[28]
Eysenbach G, K?hler C. How do consumers search for and appraise health information on the world wide web? Qualitative study using focus groups, usability tests, and in-depth interviews. BMJ 2002; 324:573-7.
[29]
Merheb S, Wang N, Weinberg J, Wang DS, Wason SEL. Online interest in surgical treatment for benign prostatic hyperplasia using Google Trends. World J Urol 2021; 39:2655-9.
Luis G. Medina, Randall A. Lee, Valeria Celis, Veronica Rodriguez, Jaime Poncel, Aref S. Sayegh, Rene Sotelo. Robotic management of urinary fistula[J]. Asian Journal of Urology, 2024, 11(3): 357
-365
.
